[go: up one dir, main page]

FI884947L - TETRAHYDRO-FURO- OCH TIENO/2,3-C/ PYRIDINER, DERAS ANVAENDNING SAOSOM LAEKEMEDEL OCH FOERFARANDE FOER DERAS FRAMSTAELLNING. - Google Patents

TETRAHYDRO-FURO- OCH TIENO/2,3-C/ PYRIDINER, DERAS ANVAENDNING SAOSOM LAEKEMEDEL OCH FOERFARANDE FOER DERAS FRAMSTAELLNING. Download PDF

Info

Publication number
FI884947L
FI884947L FI884947A FI884947A FI884947L FI 884947 L FI884947 L FI 884947L FI 884947 A FI884947 A FI 884947A FI 884947 A FI884947 A FI 884947A FI 884947 L FI884947 L FI 884947L
Authority
FI
Finland
Prior art keywords
och
deras
pyridiner
tieno
furo
Prior art date
Application number
FI884947A
Other languages
Finnish (fi)
Other versions
FI884947A0 (en
FI884947A7 (en
Inventor
Albrecht Harreus
Karl-Heinz Weber
Gerhard Walther
Werner Stransky
Franz Josef Kuhn
Guenter Schingnitz
Helmut Ensinger
Original Assignee
Boehringer Ingelheim Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Kg filed Critical Boehringer Ingelheim Kg
Publication of FI884947A0 publication Critical patent/FI884947A0/en
Publication of FI884947L publication Critical patent/FI884947L/en
Publication of FI884947A7 publication Critical patent/FI884947A7/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
FI884947A 1987-10-29 1988-10-27 Tetrahydro-furo- and -thieno/2,3-c/pyridines, their use as pharmaceuticals and method for their preparation FI884947A7 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19873736664 DE3736664A1 (en) 1987-10-29 1987-10-29 TETRAHYDRO-FURO- AND -THIENO (2,3-C) PYRIDINE, THEIR USE AS A MEDICAMENT AND METHOD FOR THE PRODUCTION THEREOF

Publications (3)

Publication Number Publication Date
FI884947A0 FI884947A0 (en) 1988-10-27
FI884947L true FI884947L (en) 1989-04-30
FI884947A7 FI884947A7 (en) 1989-04-30

Family

ID=6339349

Family Applications (1)

Application Number Title Priority Date Filing Date
FI884947A FI884947A7 (en) 1987-10-29 1988-10-27 Tetrahydro-furo- and -thieno/2,3-c/pyridines, their use as pharmaceuticals and method for their preparation

Country Status (17)

Country Link
EP (1) EP0314154A3 (en)
JP (1) JPH01157983A (en)
KR (1) KR890006650A (en)
AU (1) AU2443588A (en)
CS (1) CS273193B2 (en)
DD (1) DD283395A5 (en)
DE (1) DE3736664A1 (en)
DK (1) DK603588A (en)
FI (1) FI884947A7 (en)
HU (1) HU201553B (en)
IL (1) IL88184A0 (en)
NO (1) NO884835L (en)
PL (1) PL275555A1 (en)
PT (1) PT88899B (en)
SU (1) SU1657064A3 (en)
YU (1) YU201288A (en)
ZA (1) ZA888089B (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2623810B2 (en) * 1987-02-17 1992-01-24 Sanofi Sa ALPHA SALTS- (TETRAHYDRO-4,5,6,7 THIENO (3,2-C) PYRIDYL-5) (2-CHLORO-PHENYL) -THETHYL ACETATE DEXTROGYRE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
US5272148A (en) * 1992-09-09 1993-12-21 Hoechst-Roussel Pharmaceuticals Incorporated Heteroarenylpiperazines
US8914114B2 (en) 2000-05-23 2014-12-16 The Feinstein Institute For Medical Research Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
HU227746B1 (en) * 2000-07-06 2012-02-28 Ube Industries Hydropyridine derivative acid addition salts, process for their preparation, pharmaceutical compositions containing them and their use
US20040048795A1 (en) * 2002-02-26 2004-03-11 North Shore-Long Island Jewish Research Institute Inhibition of inflammatory cytokine production by stimulation of brain muscarinic receptors
US10912712B2 (en) 2004-03-25 2021-02-09 The Feinstein Institutes For Medical Research Treatment of bleeding by non-invasive stimulation
WO2005092308A2 (en) 2004-03-25 2005-10-06 The Feinstein Institute For Medical Research Neural tourniquet
US11207518B2 (en) 2004-12-27 2021-12-28 The Feinstein Institutes For Medical Research Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
CA2593079C (en) 2004-12-27 2014-08-19 North Shore-Long Island Jewish Research Institute Treating inflammatory disorders by electrical vagus nerve stimulation
TWI392681B (en) * 2006-04-06 2013-04-11 Daiichi Sankyo Co Ltd Prasugrel with high purity and a method for preparing its acid addition salt
KR101505212B1 (en) * 2007-03-02 2015-03-23 다이이찌 산쿄 가부시키가이샤 Process for production of prasugrel hydrochloride having high purity
US8391970B2 (en) 2007-08-27 2013-03-05 The Feinstein Institute For Medical Research Devices and methods for inhibiting granulocyte activation by neural stimulation
US9662490B2 (en) 2008-03-31 2017-05-30 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
WO2009146030A1 (en) 2008-03-31 2009-12-03 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation of t-cell activity
US9211410B2 (en) 2009-05-01 2015-12-15 Setpoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US8996116B2 (en) 2009-10-30 2015-03-31 Setpoint Medical Corporation Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
WO2010144578A2 (en) 2009-06-09 2010-12-16 Setpoint Medical Corporation Nerve cuff with pocket for leadless stimulator
US9833621B2 (en) 2011-09-23 2017-12-05 Setpoint Medical Corporation Modulation of sirtuins by vagus nerve stimulation
WO2014169145A1 (en) 2013-04-10 2014-10-16 Setpoint Medical Corporation Closed-loop vagus nerve stimulation
CN102821814B (en) 2009-12-23 2015-07-15 赛博恩特医疗器械公司 Neurostimulation devices and systems for treating chronic inflammation
WO2012154865A2 (en) 2011-05-09 2012-11-15 Setpoint Medical Corporation Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US12172017B2 (en) 2011-05-09 2024-12-24 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
US9572983B2 (en) 2012-03-26 2017-02-21 Setpoint Medical Corporation Devices and methods for modulation of bone erosion
US11311725B2 (en) 2014-10-24 2022-04-26 Setpoint Medical Corporation Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
WO2016126807A1 (en) 2015-02-03 2016-08-11 Setpoint Medical Corporation Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
US10596367B2 (en) 2016-01-13 2020-03-24 Setpoint Medical Corporation Systems and methods for establishing a nerve block
CN114904142A (en) 2016-01-20 2022-08-16 赛博恩特医疗器械公司 Control of vagus nerve stimulation
WO2017127758A1 (en) 2016-01-20 2017-07-27 Setpoint Medical Corporation Implantable microstimulators and inductive charging systems
US11471681B2 (en) 2016-01-20 2022-10-18 Setpoint Medical Corporation Batteryless implantable microstimulators
US10583304B2 (en) 2016-01-25 2020-03-10 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
EP3668402B1 (en) 2017-08-14 2024-07-31 Setpoint Medical Corporation Vagus nerve stimulation pre-screening test
US11260229B2 (en) 2018-09-25 2022-03-01 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
AU2020272128B9 (en) 2019-04-12 2025-11-20 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
US11938324B2 (en) 2020-05-21 2024-03-26 The Feinstein Institutes For Medical Research Systems and methods for vagus nerve stimulation
WO2022245878A1 (en) 2021-05-17 2022-11-24 Setpoint Medical Corporation Neurostimulation parameter authentication and expiration system for neurostimulation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2315274A1 (en) * 1975-06-27 1977-01-21 Parcor NEW DERIVATIVES OF THIENO (2,3-C) PYRIDINE, THEIR PREPARATION AND THEIR APPLICATIONS
FR2317303A1 (en) * 1975-07-09 1977-02-04 Parcor PROCESS FOR PREPARING TETRAHYDROTHIENO (3,2-C) AND (2,3-C) PYRIDINE DERIVATIVES

Also Published As

Publication number Publication date
HUT50824A (en) 1990-03-28
EP0314154A2 (en) 1989-05-03
DK603588A (en) 1989-04-30
IL88184A0 (en) 1989-06-30
KR890006650A (en) 1989-06-15
ZA888089B (en) 1990-07-25
HU201553B (en) 1990-11-28
PL275555A1 (en) 1989-05-02
DK603588D0 (en) 1988-10-28
FI884947A0 (en) 1988-10-27
CS273193B2 (en) 1991-03-12
DE3736664A1 (en) 1989-05-11
JPH01157983A (en) 1989-06-21
PT88899B (en) 1993-01-29
EP0314154A3 (en) 1990-12-05
NO884835D0 (en) 1988-10-28
FI884947A7 (en) 1989-04-30
DD283395A5 (en) 1990-10-10
NO884835L (en) 1989-05-02
SU1657064A3 (en) 1991-06-15
YU201288A (en) 1990-08-31
CS712688A2 (en) 1990-06-13
AU2443588A (en) 1989-07-13

Similar Documents

Publication Publication Date Title
FI884947L (en) TETRAHYDRO-FURO- OCH TIENO/2,3-C/ PYRIDINER, DERAS ANVAENDNING SAOSOM LAEKEMEDEL OCH FOERFARANDE FOER DERAS FRAMSTAELLNING.
FI884487A7 (en) KATALYSATORER, FOERFARANDE FOER DERAS FRAMSTAELLNING OCH ANVAENDNING.
FI890094A0 (en) CYLINDRISK, NMR-BIASERINGSMAGNETANORDNING UTNYTTJANDE PERMANENTA MAGNETAR OCH FOERFARANDE FOER DENSAMMA.
FI882690A7 (en) POLYOLEFINER INNEHAOLLANDE FUNKTIONEN GRUPPER, MASKERADE MONOMERER INNEHAOLLANDE FUNKTIONEN GRUPPER, REAKTIONSBLANDNINGAR OCH FOERFARANDEN FOER DERAS FRAMSTAELLNING.
FI880198A7 (en) VATTENHALTIGA BLEKMEDELSUSPENSIONER INNEHAOLLANDE PEROXIKARBOXYLSYROR, FOERFARANDE FOER DERAS FRAMSTAELLNING OCH DERAS ANVAENDNING.
FI881380L (en) 1,4-DISUBSTITUERADE PIPERAZINFOERENINGAR, DERAS FRAMSTAELLNING OCH ANVAENDNING.
FI881086A0 (en) OLJA-I-VATTEN-EMULSIONER, FOERFARANDE FOER DERAS FRAMSTAELLNING OCH DERAS ANVAENDNING.
FI894566A7 (en) SUBSTITUERADE BENZAZEPINER, DERAS FRAMSTAELLNING OCH DESSA INNEHAOLLANDE FARMACEUTISKA BLANDNINGAR.
FI884886A0 (en) KALIUMKARBONATBAERARE, KALIUMKATALYTER OCH MEDELST DESSA UTFOERDA OLEFINDIMERISERINGSPROCESSER.
FI870546A0 (en) 1,4-BENZOZAZINDERIVAT, DERAS FRAMSTAELLNING OCH ANVAENDNING.
FI884505A0 (en) IMMUNOANALYS, I VILKEN ANVAENDS IGG-UPPSNAPPANDE ANTIKROPPAR OCH DETEKTERINGSSYSTEM FOER FLERA MONOCLONALA ANTIKROPPAR.
FI871081A0 (en) 1,1-DISUBSTITUERADE CYKLOPROPANDERIVAT, DERAS FRAMSTAELLNINGSFOERFARANDE OCH ANVAENDNING.
FI885592L (en) ARYLOXYPHENYLPROPYLAMINER, DERAS FRAMSTAELLNING OCH ANVAENDNING.
FI885596A7 (en) MANUMYCINDERIVAT, FOERFARANDE FOER DERAS FRAMSTAELLNING OCH DERAS ANVAENDNING.
FI880525L (en) SUBSTITUERADE AMINDERIVAT, DERAS FRAMSTAELLNING OCH ANVAENDNING.
FI882442L (en) ELLEDANDE BELAEGGNINGSMASSA, FOERFARANDE FOER FRAMSTAELLNING OCH ANVAENDNING DAERAV.
FI880199A7 (en) VATTENHALTIGA BLEKMEDELSUSPENSIONER INNEHAOLLANDE PEROXIKARBOXYLSYROR, FOERFARANDE FOER DERAS FRAMSTAELLNING OCH DERAS ANVAENDNING.
FI882715A0 (en) FENOLDERIVAT, DERAS FRAMSTAELLNING OCH ANVAENDNING.
FI881609A7 (en) DIHYDROPYRIDINAMIDER, FOERFARANDE FOER DERAS FRAMSTAELLNING OCH DERAS ANVAENDNING I LAEKEMEDEL.
FI884863A7 (en) KONDENSERADE DIAZEPINONER, FOERFARANDE FOER DERAS FRAMSTAELLNING OCH DESSA FOERENINGAR INNEHAOLLANDE LAEKEMEDEL.
FI883986A0 (en) TRICYCLIS FUSIONERADE PYRIMIDINDERIVAT, DERAS FRAMSTAELLNING OCH ANVAENDNING.
FI892949A0 (en) 2,5,6,7-TETRANOR-4,8-INTER-M-PHENYLENE-PG12-DERIVATIVES, FOERFARANDE FOER DESS FRAMSTAELLNING OCH DESS ANVAENDNING.
FI883812A7 (en) 4'-DESHYDROXIEPIPODOPHYLLOTOXIN -GLUCOSIDER, SYNTES OCH ANVAENDNING.
FI884455A0 (en) RENIN-HAEMMANDE DIPEPTIDER, FOERFARANDE FOER DERAS FRAMSTAELLNING, DESSA INNEHAOLLANDE CEEKEMEDEL OCH DERAS ANVAENDNING.
FI871448A7 (en) BIS-TERTIAERBUTYLAMINOSUBSTITUERADE 1,3,5-TRIAZINDERIVAT, FOERFARANDEN FOER DERAS FRAMSTAELLNING, DESSA FOERENINGAR INNEHAOLLANDE LAEKEMEDEL OCH DERAS ANVAENDNING.

Legal Events

Date Code Title Description
MM Patent lapsed

Owner name: BOEHRINGER INGELHEIM KG